• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估 1 型糖尿病发病前的 T 细胞反应。

Evaluating T cell responses prior to the onset of type 1 diabetes.

机构信息

Department of Immunobiology, King's College London, London, UK.

School of Clinical Sciences, University of Bristol, Bristol, UK.

出版信息

Diabet Med. 2022 Sep;39(9):e14860. doi: 10.1111/dme.14860. Epub 2022 May 9.

DOI:10.1111/dme.14860
PMID:35477909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9542909/
Abstract

AIMS

In the current study we aimed to evaluat T cell phenotypes and metabolic profiles in high-risk individuals who progressed to type 1 diabetes compared to those remaining disease free.

METHODS

A Fluorspot assay was used to examine T cell responses to a panel of islet autoantigen peptides in samples obtained 6- and 30-months preceding disease onset and at the same timepoints in non-progressors.

RESULTS

We noted a significant increase in the magnitude of the proinflammatory interferon-γ response to proinsulin and insulin peptides in individuals who progressed to type 1 diabetes. In contrast, in the non-progressors, we observed an increase in the regulatory IL-10 response to proinsulin peptides. Furthermore, the T cell responses to the islet peptide panel predisposed towards a proinflammatory interferon-γ bias in the progressors.

CONCLUSIONS

Collectively, these data suggest that a proinflammatory T cell response is prevalent in high-risk individuals who progress to type 1 diabetes and can be detected up to 6 months prior to onset of disease. This observation, albeit in a small cohort, can potentially be harnessed in disease staging, particularly in identifying autoantibody-positive individuals transitioning from stage 2 (dysglycemia present and pre-symptomatic) to stage 3 (dysglycemia present and symptomatic). The detection of these different T cell phenotypes in progressors and non-progressors suggests the presence of disease endotypes.

摘要

目的

本研究旨在评估与无疾病进展者相比,进展为 1 型糖尿病的高危个体的 T 细胞表型和代谢特征。

方法

使用 Fluorspot assay 检测在疾病发病前 6 个月和 30 个月以及非进展者同期获得的样本中,T 细胞对胰岛自身抗原肽的反应。

结果

我们注意到,在进展为 1 型糖尿病的个体中,对前胰岛素和胰岛素肽的促炎干扰素-γ反应幅度显著增加。相比之下,在非进展者中,我们观察到前胰岛素肽的调节性 IL-10 反应增加。此外,胰岛肽组的 T 细胞反应倾向于进展者的促炎干扰素-γ偏向。

结论

总之,这些数据表明,进展为 1 型糖尿病的高危个体中存在促炎 T 细胞反应,并且可以在疾病发病前 6 个月检测到。尽管在一个小队列中观察到这种情况,但它可能在疾病分期中得到利用,特别是在识别从第 2 阶段(存在血糖异常和无症状)向第 3 阶段(存在血糖异常和有症状)过渡的自身抗体阳性个体。在进展者和非进展者中检测到这些不同的 T 细胞表型提示存在疾病终末类型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a599/9542909/61ed774d4e7c/DME-39-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a599/9542909/6d57eff71359/DME-39-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a599/9542909/61ed774d4e7c/DME-39-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a599/9542909/6d57eff71359/DME-39-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a599/9542909/61ed774d4e7c/DME-39-0-g002.jpg

相似文献

1
Evaluating T cell responses prior to the onset of type 1 diabetes.评估 1 型糖尿病发病前的 T 细胞反应。
Diabet Med. 2022 Sep;39(9):e14860. doi: 10.1111/dme.14860. Epub 2022 May 9.
2
Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8 T cells and exhibit a distinct CD95 B cell phenotype.1型糖尿病进展缓慢者会随着时间推移失去胰岛自身抗体,胰岛抗原特异性CD8 T细胞数量较少,并表现出独特的CD95 B细胞表型。
Diabetologia. 2020 Jun;63(6):1174-1185. doi: 10.1007/s00125-020-05114-7. Epub 2020 Mar 10.
3
IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes.1 型糖尿病患者自身抗体阴性一级亲属的 IFN-γ 和 IL-10 胰岛抗原特异性 T 细胞应答。
Diabetologia. 2010 Jul;53(7):1451-60. doi: 10.1007/s00125-010-1739-3. Epub 2010 Apr 6.
4
Relationship between T and B cell responses to proinsulin in human type 1 diabetes.人类1型糖尿病中T细胞和B细胞对胰岛素原反应之间的关系。
Ann N Y Acad Sci. 2003 Nov;1005:288-94. doi: 10.1196/annals.1288.045.
5
Humoral and cellular immune responses to proinsulin in adults with newly diagnosed type 1 diabetes.新诊断1型糖尿病成人患者对胰岛素原的体液免疫和细胞免疫反应。
Diabetes Metab Res Rev. 2003 Jan-Feb;19(1):52-9. doi: 10.1002/dmrr.332.
6
T-cell responses to hybrid insulin peptides prior to type 1 diabetes development.T 细胞对 1 型糖尿病发病前的混合胰岛素肽的反应。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2019129118.
7
Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.胰岛素原多肽免疫疗法可诱导抗原特异性调节性T细胞,并在人源化模型中限制自身免疫。
Clin Exp Immunol. 2015 Dec;182(3):251-60. doi: 10.1111/cei.12687. Epub 2015 Sep 17.
8
Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.自身反应性T细胞反应在糖尿病中表现出促炎极化,但在健康状态下表现出调节性表型。
J Clin Invest. 2004 Feb;113(3):451-63. doi: 10.1172/JCI19585.
9
Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.鉴定 HLA 相关疾病易感性儿童中 1 型糖尿病的快速进展者。
Diabetologia. 2017 Jul;60(7):1284-1293. doi: 10.1007/s00125-017-4258-7. Epub 2017 Mar 31.
10
Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes.来自两种β细胞自身抗原(胰岛素原和谷氨酸脱羧酶)的相似肽段,可刺激有胰岛素依赖型糖尿病风险个体的T细胞。
Mol Med. 1995 Sep;1(6):625-33.

引用本文的文献

1
Heterogeneity and endotypes in type 1 diabetes mellitus.1 型糖尿病的异质性和内型。
Nat Rev Endocrinol. 2023 Sep;19(9):542-554. doi: 10.1038/s41574-023-00853-0. Epub 2023 Jun 19.
2
Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials.监测 1 型糖尿病临床免疫治疗试验中的胰岛特异性免疫反应。
Front Immunol. 2023 May 22;14:1183909. doi: 10.3389/fimmu.2023.1183909. eCollection 2023.

本文引用的文献

1
Proinsulin-specific T-cell responses correlate with estimated c-peptide and predict partial remission duration in type 1 diabetes.胰岛素原特异性T细胞反应与估算的C肽相关,并可预测1型糖尿病的部分缓解持续时间。
Clin Transl Immunology. 2021 Jul 26;10(7):e1315. doi: 10.1002/cti2.1315. eCollection 2021.
2
Mapping T Cell Responses to Native and Neo-Islet Antigen Epitopes in at Risk and Type 1 Diabetes Subjects.在高危人群和 1 型糖尿病患者中,对天然和新胰岛抗原表位的 T 细胞反应的研究。
Front Immunol. 2021 Jun 25;12:675746. doi: 10.3389/fimmu.2021.675746. eCollection 2021.
3
Current and future therapies for type 1 diabetes.
1 型糖尿病的当前和未来疗法。
Diabetologia. 2021 May;64(5):1037-1048. doi: 10.1007/s00125-021-05398-3. Epub 2021 Feb 17.
4
T-cell responses to hybrid insulin peptides prior to type 1 diabetes development.T 细胞对 1 型糖尿病发病前的混合胰岛素肽的反应。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2019129118.
5
The clinical consequences of heterogeneity within and between different diabetes types.不同糖尿病类型内部和之间异质性的临床后果。
Diabetologia. 2020 Oct;63(10):2040-2048. doi: 10.1007/s00125-020-05211-7. Epub 2020 Sep 7.
6
C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.在 TrialNet 中,对 1 型糖尿病诊断前后进行长期随访的受试者的 C 肽水平。
Diabetes Care. 2020 Aug;43(8):1836-1842. doi: 10.2337/dc19-2288. Epub 2020 May 26.
7
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.谁在入组?1 型糖尿病临床试验网络预防途径监测的入组之路。
Diabetes Care. 2019 Dec;42(12):2228-2236. doi: 10.2337/dc19-0593. Epub 2019 Sep 26.
8
Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.标准化 1 型糖尿病中的 T 细胞生物标志物:挑战与最新进展。
Diabetes. 2019 Jul;68(7):1366-1379. doi: 10.2337/db19-0119.
9
Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort.英国队列中初发1型糖尿病儿童和成人的胰岛自身抗体状态与临床特征的关系
BMJ Open. 2018 Apr 4;8(4):e020904. doi: 10.1136/bmjopen-2017-020904.
10
T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.T细胞介导的β细胞破坏:1型糖尿病背景下的自身免疫和同种免疫
Front Endocrinol (Lausanne). 2017 Dec 5;8:343. doi: 10.3389/fendo.2017.00343. eCollection 2017.